Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 15/20 | 0.88 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676272 | 0.97 | SCD (0.90) | SCDDCTPP1NPC1ALDH1A1LMNA | |
| SCHEMBL3673233 | 0.94 | SCD (1.00) | SCDDCTPP1NPC1ALDH1A1LMNA | |
| SCHEMBL3667840 | 0.90 | SCD (0.78) | SCDDCTPP1 | |
| SCHEMBL3668977 | 0.89 | SCD (0.77) | SCDDCTPP1 | |
| SCHEMBL3677043 | 0.89 | SCD (0.79) | SCDDCTPP1 | |
| SCHEMBL3666654 | 0.88 | SCD (0.68) | SCDDCTPP1NPC1ALDH1A1LMNA | |
| SCHEMBL3671099 | 0.87 | SCD (0.77) | SCDDCTPP1 | |
| SCHEMBL3670752 | 0.87 | SCD (0.67) | SCDDCTPP1NPC1ALDH1A1LMNA | |
| SCHEMBL3671848 | 0.87 | SCD (0.83) | SCDDCTPP1 | |
| SCHEMBL3668057 | 0.86 | SCD (0.75) | SCDDCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763350-B1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-12-21 | — | — | EP | claimed |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | claimed |
| CN-1997371-A | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2007-07-11 | — | — | CN | claimed |
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-06-02 | — | — | US | claimed |
| EP-1763350-B1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-12-21 | — | — | EP | disclosed |
| EP-2266566-A2 | Nicotinamide derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | disclosed |
| CN-1997371-A | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2007-07-11 | — | — | CN | disclosed |
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | NAMPT, NNT, NNMT | SCD 10/4885DCTPP1 726/4885NPC1 94/4885 |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | NAMPT, NNT, NNMT | SCD 10/4885DCTPP1 726/4885NPC1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.